相关临床试验
218
10 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1791
进行中（未招募）
2
0.9%
已完成
143
65.6%
Enrolling By Invitation
3
1.4%
尚未招募
5
2.3%
招募中
19
8.7%
暂停
1
0.5%
终止
9
4.1%
Unknown
31
14.2%
撤回
5
2.3%
暂无批准数据
- A Nature study presents the first genomic analysis of eight Myotis bat species, linking longer lifespans to stronger immune defense and cancer-suppressing gene activity. - Cells from the little brown bat responded to lethal chemical damage by activating cell-death genes rather than DNA repair, mirroring the elephant's anti-cancer strategy. - Researchers found far more overlap than expected by chance between genes associated with bat longevity and genes involved in bat-virus interactions. - Myotis bats show unusual enrichment of genes interacting with DNA viruses such as herpesviruses, a pattern opposite to humans and other primates.
- The National Science Foundation has awarded $7.9 million to establish the PFAS Environmental Research Network (PERN), a four-year initiative led by Bennington College. - The network unites Bennington College, Middlebury College, the University of Vermont, and Landmark College with state agencies to study how PFAS move through water systems and food webs. - UVM researchers will apply Bayesian analysis, machine learning, and data science to model PFAS distribution, persistence, and human exposure pathways across Vermont. - The initiative aims to generate actionable data to inform environmental management, public health decisions, and policy for "forever chemicals."
- The University of Vermont (UVM) has launched a 24-week, tuition-free Biotechnology Technician Certificate through its Professional and Continuing Education (PACE) division. - The program requires no prior science degree and blends asynchronous online coursework with hands-on lab training in UVM research facilities. - Funding comes from $2.7 million in congressional support secured by U.S. Senator Peter Welch to strengthen Vermont's life sciences talent pipeline. - Graduates gain skills in lab safety, pipetting, data analysis, chromatography, microscopy, sterile technique, and DNA work for entry-level pharmaceutical and biomanufacturing roles.
- A phase one clinical trial found that RSO-021 controlled disease progression in 67% of patients with relapsed mesothelioma, with some patients experiencing tumor shrinkage. - The drug disables the antioxidant enzyme peroxiredoxin 3 (PRX3) in tumor cell mitochondria, causing a buildup of hydrogen peroxide that selectively kills cancer cells. - Overall survival in the 15-patient cohort exceeded that seen with standard treatments, and the drug was well tolerated with no patient deaths attributed to it. - Phase two has been completed and results are expected to be presented at a global oncology meeting later this year.
- Tick-borne infections now account for more than 75% of all vector-borne disease cases in the U.S., with babesiosis cases rising dramatically alongside anaplasmosis over the past decade. - Dr. Peter Hyson received an NIH K08 award and a $150,000 Bay Area Lyme Foundation Emerging Leader Award to advance preclinical development of novel compounds targeting Babesia protein synthesis. - Current babesiosis treatments are often inadequate, with elderly and immunocompromised patients frequently relapsing after standard-of-care therapy. - If successful, the compounds under investigation could become the first drugs created specifically for babesiosis and potentially the new standard of care.
- Brazil's national drug regulator approved the world's first single-dose dengue vaccine, Butantan-DV, for use in people aged 12 to 59, marking a significant breakthrough in dengue prevention. - The vaccine demonstrated 74.7% overall efficacy and 91.6% efficacy against severe forms of dengue in late-stage trials involving 16,000 volunteers across Brazil. - The single-dose format will particularly benefit remote communities in hard-to-reach regions like the Amazon, eliminating the need for multiple clinic visits required by existing two-dose vaccines. - Brazil plans to incorporate the vaccine into its national immunization program by early 2026, with over 1 million doses ready for distribution following the country's worst dengue epidemic with 6.4 million cases and 5,972 deaths in 2024.
- A large Canadian retrospective study of 32,667 preterm infants reveals probiotics significantly reduced mortality rates, with an adjusted odds ratio of 0.62 in infants born before 34 weeks gestation. - While probiotics showed promising survival benefits, they did not significantly decrease rates of necrotizing enterocolitis or late-onset sepsis, two common complications in preterm infants. - The study found probiotic sepsis was rare, occurring in only 27 infants, though researchers emphasize the need for pharmaceutical-grade products and further research on specific probiotic strains.
